サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434544

制酸剤市場：剤形、薬剤クラス別、流通チャネル別-2024～2030年の世界予測

Antacids Market by Formulation (Liquid, Powder, Tablet), Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
制酸剤市場：剤形、薬剤クラス別、流通チャネル別-2024～2030年の世界予測
出版日: 2024年01月16日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

制酸剤市場規模は2023年に78億8,000万米ドルと推計され、2024年には82億7,000万米ドルに達し、CAGR 5.13%で2030年には111億9,000万米ドルに達すると予測されます。

制酸剤の世界市場

主な市場の統計
基準年[2023］ 78億8,000万米ドル
予測年[2024］ 82億7,000万米ドル
予測年 [2030] 111億9,000万米ドル
CAGR（%） 5.13%
制酸剤 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは制酸剤市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、制酸剤市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-制酸剤市場の市場規模および予測は？

2-制酸剤市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-制酸剤市場における技術動向と規制の枠組みは？

4-制酸剤市場における主要ベンダーの市場シェアは？

5-制酸剤市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 不健康なライフスタイルの選択や酸性度を引き起こす薬物の摂取により、胃食道逆流症（GERD）に苦しむ人口が増加
      • GERDについての認識を高める情報の増加
      • 制酸剤を要求される、座りっぱなしでストレスの多いライフスタイル
    • 抑制要因
      • 酸性度関連の問題に対する家庭療法やその他の代替手段の入手可能性
    • 機会
      • より即効性と持続性のある制酸剤の開発
      • オンライン薬局での制酸剤の容易な利用と、OTC医薬品の規制の柔軟性
    • 課題
      • 制酸剤に関連する重大な健康副作用によるFDA医薬品のリコール
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 制酸剤市場配合別

  • 液体
  • 粉
  • タブレット

第7章 制酸剤市場薬剤クラス別

  • 酸中和剤
  • H2アンタゴニスト
  • 販売促進エージェント
  • プロトンポンプ阻害剤

第8章 制酸剤市場：流通チャネル別

  • 病院薬局
  • 小売薬局

第9章 南北アメリカの制酸剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の制酸剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの制酸剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Alardius Healthcare
    • Bayer AG
    • Biozenta Lifescience PVT LTD
    • Boehringer Sohn AG & Ko. KG
    • Cadila Pharmaceuticals Limited
    • GlaxoSmithKline PLC
    • GM Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Pfizer Inc.
    • Procter and Gamble Company
    • Sanofi-Aventis Groupe S.A.
    • Torrent Pharmaceuticals Ltd.
    • Uniroyal Biotech
    • WellSpring Pharmaceutical Corporation
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTACIDS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTACIDS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTACIDS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTACIDS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTACIDS MARKET DYNAMICS
  • FIGURE 7. ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 8. ANTACIDS MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 10. ANTACIDS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTACIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTACIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTACIDS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 6. ANTACIDS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTACIDS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTACIDS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 10. ANTACIDS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTACIDS MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTACIDS MARKET SIZE, BY PROMOTILITY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTACIDS MARKET SIZE, BY PROTON PUMP INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. ANTACIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTACIDS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTACIDS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTACIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ANTACIDS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTACIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. ANTACIDS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 145. ANTACIDS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. ANTACIDS MARKET LICENSE & PRICING
目次
Product Code: MRR-4358BACA7E48

[186 Pages Report] The Antacids Market size was estimated at USD 7.88 billion in 2023 and expected to reach USD 8.27 billion in 2024, at a CAGR 5.13% to reach USD 11.19 billion by 2030.

Global Antacids Market

KEY MARKET STATISTICS
Base Year [2023] USD 7.88 billion
Estimated Year [2024] USD 8.27 billion
Forecast Year [2030] USD 11.19 billion
CAGR (%) 5.13%
Antacids Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antacids Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antacids Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Alardius Healthcare, Bayer AG, Biozenta Lifescience PVT LTD, Boehringer Sohn AG & Ko. KG, Cadila Pharmaceuticals Limited, GlaxoSmithKline PLC, GM Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Procter and Gamble Company, Sanofi-Aventis Groupe S.A., Torrent Pharmaceuticals Ltd., Uniroyal Biotech, and WellSpring Pharmaceutical Corporation.

Market Segmentation & Coverage

This research report categorizes the Antacids Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Formulation
    • Liquid
    • Powder
    • Tablet
  • Drug Class
    • Acid Neutralizers
    • H2 Antagonist
    • Promotility Agents
    • Proton Pump Inhibitor
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antacids Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antacids Market?

3. What are the technology trends and regulatory frameworks in the Antacids Market?

4. What is the market share of the leading vendors in the Antacids Market?

5. Which modes and strategic moves are suitable for entering the Antacids Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antacids Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing population suffering from gastroesophageal reflux disease, or GERD due to unhealthy lifestyle choices and consumption of drugs resulting in acidity
      • 5.1.1.2. Increasing information creating awareness about GERD
      • 5.1.1.3. Sedentary and stressed lifestyle demanding antacids
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of home remedies and other alternatives for acidity related issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of more instantly effective and long lasting antacids
      • 5.1.3.2. Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
    • 5.1.4. Challenges
      • 5.1.4.1. FDA drug recall due to significant health side effects associated with the antacids
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antacids Market, by Formulation

  • 6.1. Introduction
  • 6.2. Liquid
  • 6.3. Powder
  • 6.4. Tablet

7. Antacids Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Acid Neutralizers
  • 7.3. H2 Antagonist
  • 7.4. Promotility Agents
  • 7.5. Proton Pump Inhibitor

8. Antacids Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Retail Pharmacy

9. Americas Antacids Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antacids Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antacids Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Alardius Healthcare
    • 13.1.2. Bayer AG
    • 13.1.3. Biozenta Lifescience PVT LTD
    • 13.1.4. Boehringer Sohn AG & Ko. KG
    • 13.1.5. Cadila Pharmaceuticals Limited
    • 13.1.6. GlaxoSmithKline PLC
    • 13.1.7. GM Pharmaceuticals, Inc.
    • 13.1.8. Johnson & Johnson Services, Inc.
    • 13.1.9. Novartis AG
    • 13.1.10. Pfizer Inc.
    • 13.1.11. Procter and Gamble Company
    • 13.1.12. Sanofi-Aventis Groupe S.A.
    • 13.1.13. Torrent Pharmaceuticals Ltd.
    • 13.1.14. Uniroyal Biotech
    • 13.1.15. WellSpring Pharmaceutical Corporation
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing